SOUTH SAN FRANCISCO, Calif.,
Sept. 27, 2018 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced
that it will host an investor and analyst day event on Thursday, October 4, 2018 from 12:00pm to 2:30pm Eastern Time in New York City. Members of Rigel's management
team and leading clinical experts will provide updates on the
company's recent launch of TAVALISSETM, development
program for fostamatinib in the treatment of autoimmune hemolytic
anemia, and strategy for pipeline expansion.
The event will feature presentations from Dr. David Kuter, Director of Clinical Hematology at
Massachusetts General Hospital and Professor of Medicine at
Harvard Medical School; and Dr.
Amit Mehta, Board-Certified
Hematologist and Medical Oncologist at Premier Hematology,
Cary, N.C., which is affiliated
with Duke University Hospital.
Space for the event is limited, therefore, a reservation is
required. Institutional investors and analysts who would like to
attend the event please contact David
Burke at dburke@rigel.com.
A live webcast of the event, with accompanying slides, will be
accessible by visiting the "Investors" section of the company's
website at https://ir.rigel.com. A replay of the webcast will also
be available and archived on the site.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is TAVALISSE™
(fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase
(SYK) inhibitor, for the treatment of adult patients with chronic
immune thrombocytopenia who have had an insufficient response to a
previous treatment. Rigel's current clinical programs include Phase
2 studies of fostamatinib in autoimmune hemolytic anemia and IgA
nephropathy. In addition, Rigel has product candidates in
development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris
Therapeutics.
Please see www.TAVALISSE.com for full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-host-investor--analyst-day-in-new-york-city-on-october-4-2018-300719972.html
SOURCE Rigel Pharmaceuticals, Inc.